Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.61
(0.29%)
CNY 44.61
(0.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.72 Billion CNY | -4.06% |
| 2022 | 2.8 Billion CNY | 23.69% |
| 2021 | 2.27 Billion CNY | 49.95% |
| 2020 | 1.51 Billion CNY | 16.22% |
| 2019 | 1.3 Billion CNY | 31.37% |
| 2018 | 991.74 Million CNY | 36.9% |
| 2017 | 724.42 Million CNY | 62.19% |
| 2016 | 446.66 Million CNY | 5.78% |
| 2015 | 422.25 Million CNY | 42.86% |
| 2014 | 295.56 Million CNY | 94.84% |
| 2013 | 151.69 Million CNY | 22.19% |
| 2012 | 124.14 Million CNY | 34.71% |
| 2011 | 92.16 Million CNY | 55.99% |
| 2010 | 59.08 Million CNY | 144.88% |
| 2009 | 24.12 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 637.23 Million CNY | -3.73% |
| 2024 Q1 | 620.42 Million CNY | 17.22% |
| 2024 Q2 | 661.95 Million CNY | 6.69% |
| 2023 Q4 | 529.29 Million CNY | -33.71% |
| 2023 FY | 2.69 Billion CNY | -4.06% |
| 2023 Q1 | 715.52 Million CNY | 11.82% |
| 2023 Q2 | 765.56 Million CNY | 6.99% |
| 2023 Q3 | 798.47 Million CNY | 4.3% |
| 2022 Q2 | 721.02 Million CNY | 2.15% |
| 2022 FY | 2.8 Billion CNY | 23.69% |
| 2022 Q4 | 639.89 Million CNY | -13.73% |
| 2022 Q3 | 741.69 Million CNY | 2.87% |
| 2022 Q1 | 705.84 Million CNY | 3.36% |
| 2021 Q2 | 554.96 Million CNY | 31.13% |
| 2021 Q1 | 423.2 Million CNY | 6.09% |
| 2021 Q3 | 609.55 Million CNY | 9.84% |
| 2021 Q4 | 682.93 Million CNY | 12.04% |
| 2021 FY | 2.27 Billion CNY | 49.95% |
| 2020 Q1 | 300.61 Million CNY | -14.19% |
| 2020 Q3 | 411.77 Million CNY | 2.19% |
| 2020 FY | 1.51 Billion CNY | 16.22% |
| 2020 Q4 | 398.89 Million CNY | -3.13% |
| 2020 Q2 | 402.95 Million CNY | 34.04% |
| 2019 Q4 | 350.33 Million CNY | 10.64% |
| 2019 FY | 1.3 Billion CNY | 31.37% |
| 2019 Q3 | 316.63 Million CNY | -12.98% |
| 2019 Q2 | 363.86 Million CNY | 33.74% |
| 2019 Q1 | 272.06 Million CNY | -12.65% |
| 2018 Q1 | 212.58 Million CNY | -2.38% |
| 2018 Q4 | 311.48 Million CNY | 50.53% |
| 2018 FY | 991.74 Million CNY | 36.9% |
| 2018 Q3 | 206.93 Million CNY | -20.64% |
| 2018 Q2 | 260.74 Million CNY | 22.65% |
| 2017 Q3 | 185.95 Million CNY | 10.29% |
| 2017 Q4 | 217.77 Million CNY | 17.12% |
| 2017 FY | 724.42 Million CNY | 62.19% |
| 2017 Q1 | 152.09 Million CNY | 52.52% |
| 2017 Q2 | 168.6 Million CNY | 10.85% |
| 2016 Q2 | 114.72 Million CNY | -4.59% |
| 2016 Q3 | 111.97 Million CNY | -2.39% |
| 2016 FY | 446.66 Million CNY | 5.78% |
| 2016 Q4 | 99.72 Million CNY | -10.95% |
| 2016 Q1 | 120.24 Million CNY | 5.46% |
| 2015 Q4 | 114.01 Million CNY | 7.64% |
| 2015 Q2 | 103.74 Million CNY | 5.26% |
| 2015 Q1 | 98.56 Million CNY | 5.32% |
| 2015 FY | 422.25 Million CNY | 42.86% |
| 2015 Q3 | 105.92 Million CNY | 2.1% |
| 2014 Q4 | 93.58 Million CNY | 8.96% |
| 2014 Q3 | 85.89 Million CNY | 45.31% |
| 2014 Q2 | 59.1 Million CNY | 3.74% |
| 2014 FY | 295.56 Million CNY | 94.84% |
| 2014 Q1 | 56.97 Million CNY | 38.89% |
| 2013 Q2 | 40.31 Million CNY | 12.2% |
| 2013 FY | 151.69 Million CNY | 22.19% |
| 2013 Q4 | 41.02 Million CNY | 19.15% |
| 2013 Q3 | 34.43 Million CNY | -14.59% |
| 2013 Q1 | 35.92 Million CNY | 6.08% |
| 2012 Q2 | 30.72 Million CNY | 13.94% |
| 2012 FY | 124.14 Million CNY | 34.71% |
| 2012 Q4 | 33.87 Million CNY | 3.93% |
| 2012 Q3 | 32.59 Million CNY | 6.08% |
| 2012 Q1 | 26.96 Million CNY | 16.64% |
| 2011 Q3 | 23.22 Million CNY | 0.0% |
| 2011 FY | 92.16 Million CNY | 55.99% |
| 2011 Q4 | 23.11 Million CNY | -0.45% |
| 2010 FY | 59.08 Million CNY | 144.88% |
| 2009 FY | 24.12 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 34.433% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | -306.76% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | -109.36% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | -226.285% |
| Maccura Biotechnology Co.Ltd | 1.51 Billion CNY | -80.108% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.72 Billion CNY | -57.866% |
| Guangdong Hybribio Biotech Co.,Ltd. | 662.35 Million CNY | -311.026% |
| BGI Genomics Co., Ltd. | 2.17 Billion CNY | -25.423% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | -212.371% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 329.31 Million CNY | -726.7% |